NovoMedix’s clinical candidates have novel biological response profiles
NovoMedix discovers and develops proprietary small molecules that target key regulatory pathways in incurable diseases. Our initial focus is metastatic triple negative breast cancer (mTNBC) and treatment of acute lung injury (ALI). mTNBC is considered incurable with a median survival of 8-13 months. These first-in-class drug candidates effectively treat primary and metastatic TNBC alone or in combination with other cancer drugs in animal models by blocking the pro-survival and immune suppressive effects of the tumor microenvironment that drive cancer progression. In addition, NM drugs reduce chemotherapy-induced cardiotoxicity and thereby improve survival and long term outcomes for TNBC patients. The leading cause of mortality in acute respiratory infections is complications from ALI resulting in respiratory and/or heart failure. Patients with underlying health conditions (asthma, COPD, obesity, diabetes, heart disease) are at higher risk than others. Further, patients who recover from severe respiratory infections may have damaged lungs and hearts with subclinical persistent injury, which could progress to fibrosis, resulting in long-term adverse outcomes that may require lung and/or heart transplant. NovoMedix clinical candidates have been shown to reduce inflammation and fibrosis in several different animal models of chronic lung and heart injury. These drugs could be used to treat ALI and decrease mortality in future respiratory infections.
Latest News
September 18, 2019
NovoMedix is the recipient of an Phase I SBIR Grant funded by the National Heart, Lung, And Blood Institute of the
National Institutes of Health (award Number R43HL147726) titled: Novel small molecules for protection against doxorubicin cardiotoxicity in TNBC .
August 26, 2019
The abstract titled
“Novel Dual MTOR Inhibitors/AMPK Activators Attenuate Doxorubicin-induced Cardiotoxicity”
has been accepted for a Rapid Fire Oral Presentation in American Heart Association Scientific Sessions on November 17, 2019.
August 12, 2018
Publication in
American Journal of Physiology Heart and Circulatory Physiology Titled
"A novel fibroblast activation inhibitor attenuates left ventricular remodeling and preserves cardiac function
in heart failure” highlights NovoMedix’s novel antifibrotic small molecule program that effectively prevents
fibroblast activation. A lead compound reduced the formation of cardiac fibrosis and preserved cardiac
function in a murine model of transaortic constriction induced heart failure with reduced ejection fraction.
The unique combination of biological activities of these compounds should have significant impact not only in heart
failure but in malignant tumors that are highly dependent on the stroma such as pancreatic and breast cancer; as well as
fibrotic disease that affect other major organs such as liver, lung, and kidney.